Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib PK Interaction Study with Digoxin, Rosuvastatin, and Metformin
NCT04231435Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fedratinib in myelofibrosis (MF), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration at 96 hours, Area Under the Concentration-Time Curve at 96 hours and 2 more. Started Dec 2019; status: completed.
02
Drugs
fedratinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04231435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231435.